

February 01, 2024

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter & Nine Months ended December 31, 2023**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2023.

We request you to please take the same on record.

Thanking You,  
Yours Faithfully,

**For Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**

*Encl.: As above*

**Dr Lal PathLabs Limited records revenue of Rs 539 Cr in Q3 FY 2023-24**

New Delhi, India, Feb 1, 2024 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2023.

**Consolidated Performance Highlights: Q3 FY 2023-24 vs Q3 FY 2022-23**

- Revenue increased by 10.1% in Q3 FY24
- EBITDA increased by 24.6% with a margin of 26.1%
- PAT increased by 53.3% with a margin for of 15.3%

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q3			YTD		
	FY24	FY23	Gr %	FY24	FY23	Gr %
<b>Revenue</b>	<b>539</b>	<b>489</b>	<b>10.1%</b>	<b>1681</b>	<b>1526</b>	<b>10.2%</b>
<b>Operating Expenditure</b>	<b>398</b>	<b>376</b>	<b>5.8%</b>	<b>1217</b>	<b>1152</b>	<b>5.6%</b>
<b>EBITDA</b>	<b>141</b>	<b>113</b>	<b>24.6%</b>	<b>465</b>	<b>374</b>	<b>24.1%</b>
<i>Margins</i>	26.1%	23.1%		27.6%	24.5%	
Other Income	18	11		51	28	
Depreciation Cost	36	38		107	113	
<b>EBIT</b>	<b>123</b>	<b>86</b>	<b>43.8%</b>	<b>408</b>	<b>289</b>	<b>41.2%</b>
<i>Margins</i>	22.8%	17.5%		24.3%	19.0%	
Finance Cost	7	9		23	28	
<b>PBT</b>	<b>116</b>	<b>76</b>	<b>51.6%</b>	<b>386</b>	<b>261</b>	<b>47.9%</b>
<i>Margins</i>	21.5%	15.6%		22.9%	17.1%	
<b>PAT</b>	<b>82</b>	<b>54</b>	<b>53.3%</b>	<b>277</b>	<b>184</b>	<b>50.1%</b>
<i>Margins</i>	15.3%	11.0%		16.4%	12.1%	
<b>EPS</b>	<b>9.8</b>	<b>6.4</b>	<b>53.2%</b>	<b>32.9</b>	<b>22.0</b>	<b>49.5%</b>



## About Dr Lal PathLabs Limited

---

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2023 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Goel  
Group Chief Financial Officer  
*Dr Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Kritika Khatwani  
*Adfactors PR*

+91 8604801332  
[kritika.khatwani@adfactorspr.com](mailto:kritika.khatwani@adfactorspr.com)

For further information on Dr Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.